AgeX Therapeutics, Inc.

Go to AgeX Therapeutics, Inc. Website

$11.10

(%)
Live
Previous Close

$11.1

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$

Day Vol.

Previous Day Vol.

Currency

Primary Exchange

NYSE American, LLC

...


Community
  • 0 posts discussing
0

Watchers

0

Visitors


Recent News

ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights.

Related tickers: AGE.

Read Full Article

Shares of International Business Machines Corporation (NYSE: IBM) shares rose sharply in today’s pre-market trading as the company reported reported stronger-than-expected results for its fourth quarter. IBM said fourth-quarter revenue increased 4% year-over-year to $17.38 billion, which beat the consensus estimate of $17.3 billion, according to Benzinga Pro. The company noted that the continued adoption of hybrid cloud and AI offerings drove its strong revenue results. IBM reported quarterly adjusted earnings of $3.87 per share versus estimates of $3.78 per share. IBM shares jumped 7.4% to $186.82 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers C3is Inc. (NASDAQ: CISS) gained 48.6% to $0.1970 in pre-market trading. Aegis Capital Corp. acted as sole bookrunner on an upsized $7.0 million underwritten public offering for C3is. Charge Enterprises, Inc. (NASDAQ: CRGE) gained 42% to $0.2090 in pre-market trading following a 6% decline on Wednesday. Acutus Medical, Inc. (NASDAQ: AFIB) shares jumped 39% to $0.3085 in pre-market trading. Acutus Medical has been granted European patent number EP3043701 titled "Devices and Methods ...

Related tickers: EFSH, AFIB, AMSC, CCCS, COLB, CISS, HXL, VSME, IBM, GVH, LPL, NOK, TSLA, PHUN, ONCO, CRGE, SPCB, AGE, CTM, AKTS.

Read Full Article
Trending Tickers

Please sign in to view